Purchase this article with an account.
Albert Jun; Future therapy: gene editing. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3918.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Genome editing with CRISPR-Cas9 has received much recent attention in biology and medicine. Our laboratory has been studying approaches using CRISPR-Cas9 to potentially treat Fuchs endothelial corneal dystrophy caused by trinucleotide repeat expansions in the TCF4 gene. Efficiency and accuracy of genome editing to remove the trinucleotide repeat region in the TCF4 gene will be presented.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only